Day: October 29, 2020

Selected HighlightsThird quarter net income of $7.5 million and Operating EBITDA* of $45.6 millionRecord Wood Segment ResultsCash on hand and available credit facilities provide liquidity of about $600.6 million at September 30, 2020NEW YORK, Oct. 29, 2020 (GLOBE NEWSWIRE) — Mercer International Inc. (Nasdaq: MERC) today reported third quarter 2020 Operating EBITDA decreased to $45.6 million from $50.8 million in the third quarter of 2019 and increased from $40.5 million in the second quarter of 2020.In the third quarter of 2020, net income was $7.5 million (or $0.11 per share) compared to $1.2 million (or $0.02 per share) in the third quarter of 2019 and a net loss of $8.4 million (or $0.13 per share) in the second quarter of 2020.In the first nine months of 2020, Operating EBITDA decreased by 41% to $143.1 million from $244.6...

GLEN HEAD, N.Y., Oct. 29, 2020 (GLOBE NEWSWIRE) — The First of Long Island Corporation (Nasdaq: FLIC), the parent company of The First National Bank of Long Island, reported net income and earnings per share for the three and nine months ended September 30, 2020. In the highlights that follow, all comparisons are of the current three or nine-month period to the same period last year unless otherwise indicated.THIRD QUARTER HIGHLIGHTSNet Income and EPS were $10.8 million and $.45, respectively, compared to $10.8 million and $.44ROA and ROE were 1.02% and 10.77%, respectively, compared to 1.02% and 10.83%Net interest margin increased 10 basis points to 2.66% from 2.56%Cost of interest-bearing deposits declined 75 basis points to .73% and cost of interest-bearing liabilities declined 60 basis points to .96%Cash Dividends Per Share increased...

SAN FRANCISCO, Oct. 29, 2020 (GLOBE NEWSWIRE) — Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), today reported its financial results for the third quarter ended September 30, 2020 and provided an update on the company’s operations.“The completion of enrollment in our Phase 3 ATTRibute-CM clinical study marks the next milestone in the accelerated development of acoramidis for patients with transthyretin (TTR) amyloidosis (ATTR),” said Neil Kumar, PhD, chief executive officer of Eidos. “Since originally licensing acoramidis from Stanford University in 2016, we have endeavored to advance the molecule as quickly as possible, knowing that every moment matters for the patients and families suffering from this devastating disease. We look forward to our top-line Phase 3 readout in just over a year and are preparing to commercialize acoramidis...

TORONTO, Oct. 29, 2020 (GLOBE NEWSWIRE) — YAMANA GOLD INC. (TSX:YRI; NYSE:AUY; LSE:AUY) (“Yamana” or “the Company”) reports its financial and operational results for the third quarter of 2020. The Company posted strong quarterly production and impressive financial performance with increased earnings, EBITDA, cash flow and free cash flow(3)  and continuing increases in cash balances.    THIRD QUARTER HIGHLIGHTSStrong Adjusted Net Earnings(1)and Cash Flows, Further Reduction in Net Debt(3)Adjusted net earnings(1) of $92.9 million or $0.10 per share basic and diluted compared to adjusted net earnings of $49.5 million or $0.05 per share basic and diluted a year earlier.Net earnings were $55.6 million or $0.06 per share basic and diluted compared to net earnings of $201.3 million or $0.21 per share basic and diluted a year earlier.(1)Strong...

EXTON, Pa., Oct. 29, 2020 (GLOBE NEWSWIRE) — Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA) today reported its financial and operational results for the third quarter ended September 30, 2020.“Tilsotolimod is the most advanced TLR-9 agonist therapy in development, and we have made tremendous strides against our objectives for 2020,” stated Vincent Milano, Idera’s Chief Executive Officer. “We continue to work diligently against our timelines for ILLUMINATE-301, which currently remain on track for data in the first quarter of 2021. In addition, our recent patent and allowed application for tilsotolimod method-of-use in colorectal and head and neck cancers as well as the continuation of ILLUMINATE-206 reinforce our ‘beyond melanoma’ strategy. We also have the financing to help our outstanding team continue to...